Consistency of atypical antipsychotic superiority to placebo in recent clinical trials

Biological Psychiatry

Volumn 49, Issue 1, 2001, Pages 64-70

  Woods, Scott W ^a,b   Stolar, Marilyn ^b,c   Sernyak, Michael J ^b,c   Charney, Dennis S ^b,c  

^a Yale University School of Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Atypical antipsychotics; Equivalence; Meta analysis; Olanzapine; Quetiapine; Risperidone

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOMES RESEARCH; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; DIBENZOTHIAZEPINES; HUMANS; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 0035063413     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)00973-2     Document Type: Article

References (37)

1. The use of placebos in clinical trials for acute schizophrenia
2. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group
3. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
4. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
5. Ici 204,636, an atypical antipsychotic - Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
6. Risperidone: Clinical safety and efficacy in schizophrenia
7. The rationale and ethics of medication-free research in schizophrenia
8. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
9. The cost of dichotomization
10. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
11. ICI 204,636, a novel, atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia
12. Stochastically dependent effect sizes
13. Another view of active-controlled trials
14. Fitting continuous models to effect size data
15. Trials to assess equivalence: The importance of rigorous methods
16. Ziprasidone 40 and 120 Mg/Day in the acute exacerbation of schizophrenia and schizoaffective disorder - A 4-week placebo controlled trial
17. To increase power in randomized clinical trials without increasing sample size
18. Is there an alternative to the randomized controlled trial?
19. Hazards of inference: The active control investigation
20. Risperidone in the treatment of schizophrenia
21. Active-controlled trials: Do they address the efficacy issue?
22. Efficacy and safety of once-daily dosing with risperidone in patients with schizophrenia (NR590)
23. Comparing effect sizes of independent studies
24. Inherent difficulties with active control equivalence studies
25. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo.
26. Placebo-controlled trials: When are they needed?
27. Government viewpoint of clinical trials
28. Difficulties in evaluating positive control trials
29. Problems in interpreting active control equivalence trials
30. When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?
31. When placebo controlled trials are essential and equivalence trials are inadequate
32. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
33. Placebo-controlled trials in schizophrenia: Are they ethical? Are they necessary?
34. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group
35. Placebo-controlled studies in schizophrenia - Ethical and scientific perspectives: An overview of conference proceedings